The issue of chronic pain is one that more and more digital health companies have sought to address, particularly as the healthcare industry seeks alternatives to opioids and surgery.
Here are some highlights from the 50+ Innovation Leaders eBook highlighting CEOs across smart living and wearables, healthcare delivery, medication management, entrepreneurial innovation and behavioral health.
Massachusetts-based Neurometrix just received 510(k) clearance from the Food and Drug Administration for over-the-counter use of its wearable gadget that treats chronic pain. The lightweight device, which is still under development and projected for commercial launch next year, emits electric jolts to the wearer. It is modeled after Sensus, the company’s device that treats pain associated with […]
The race for the first noninvasive glucose meter to hit the market is well underway and many more healthcare startups are entering the competitive diabetes treatment space. While trying to treat a large patient population, it’s still necessary to focus on the details and patient needs. It’s time to really drill down the market research […]
When Massachusetts-based Neurometrix (NURO) created a wearable device for pain management for patients suffering from diabetic peripheral neuropathy (DPN), founder and CEO Shai Gozani knew usability was key. More than a quarter of diabetic patients must cope with DPN, a burning, stabbing, acute pain, usually in the legs and feet, Gozani said. The Sensus, NURO’s nerve-stimulator […]
Nipro Corp. (TYO:8086) and NeuroMetrix Inc. (NSDQ:NURO) announced a collaboration to market NeuroMetrix’s NC-stat diagnostic nerve testing device. The NC-stat test is a quantitative point-of-care test that evaluates systemic neuropathies like diabetic peripheral neuropathy, a common disease affecting more than half of diabetics which may lead to foot ulcers and limb amputation. This may be […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
NeuroMetrix gave back $300,000 as part of a state tax incentive program. The incentive was based on the medical device company hiring 10 new people, which did not happen.
Type 2 diabetes management is the focus and neurodiagnostics is out for NeuroMetrix. The Massachusetts medical device company said it will no longer support its nerve conduction device, laid off 27 percent of its workforce and eliminated its U.S. direct salesforce. Its next device will detect diabetic neuropathy.
First quarter sales plunged and net losses soared for NeuroMetrix Inc. (NSDQ:NURO), with CEO Shai Gozani saying it may be “several quarters” before the company begins to see results from changes forced by a reimbursement rate cut. The Waltham, Mass.-based firm said revenues were off 45.6 percent for the three months ended March 31, falling […]
